Hyperthermia therapy, new cancer treatment method ‘established’
5th IVRA held, sharing clinical results of high-frequency hyperthermia cancer treatment device ‘REMISSION 1℃’
Han Sung-ho, CEO of AdipoLABs, “Delivering a message of hope to cancer patients around the world”
【Health and Welfare News】 High-frequency hyperthermia therapy is establishing itself as a new cancer treatment.
The 5th IVRA (International Virus Research Alliance) international conference was held on November 25th from 9:00 to 18:00 (local time) at the Le Meridien Hotel in Cyber Jaya, Malaysia.
In particular, this academic conference was attended by approximately 250 Korean IVRA organizing committee members as well as scholars specializing in cancer treatment from Southeast Asian countries, including Malaysia, India, and Singapore.
In addition, Malaysian government officials, broadcasting officials, and medical staff from over 10 countries shared the clinical results of ‘REMISSION 1℃’, a high-frequency hyperthermia cancer treatment device.
In Korea, about 50 medical staff including Professors Jang Hong-seok and Kang Young-nam of the Department of Radiation Oncology at the Catholic University of Korea's Seoul St. Mary's Hospital, Lee Kang-hyeon, former dean of Yonsei University Wonju University, Director Yoo Seung-mo of Yesan Myeongji Hospital in South Chungcheong Province, chairman of the IVRA organizing committee, U.S. MD Anderson tenure-track professor Kim Eui-shin, former Konkuk University Hospital director Jang Sang-geun, and Kim Seon-man of Suwon Amirang Clinic participated.
In addition, many renowned medical scholars attended, including Malaysian cancer treatment authorities Dr. Ho Gwo Fuang, Kenny Yong Yean Sirn, and Dr. Zawawi Abdullah, University of Cyberjaya Chairman Kalaiarasu Malayandi, and Indian Dr. Paramjit Kaur, Damodara Kumaran, Nagraj G. Huilgol, and N.R.Datta. On this day, the scholars shared prolific data about hyperthermia cancer treatment.
In particular, at the center of this international academic conference is Adipo LABs Co., Ltd. (CEO Han Sung-ho), the corporate representative of IVRA. AdipoLABs has been steadily exporting and donating the high-frequency hyperthermia cancer treatment device ‘REMISSION 1℃’ to each IVRA member country for the purpose of cancer treatment and clinical trials.
Through this, cancer treatment specialists have continued to publish papers on clinical results and cancer treatment effects. Finally, scholars get to have shared the results at international academic conferences of today.
A total of 20 speakers presented hyperthermia therapy methods for cancer treatment, and Professor Jang Hong-seok of Seoul St. Mary's Hospital, Dr. Nagraj G. Huilgol, Dr. Ho Gwo Fuang, and Dr. N. R. Datta exchanged various opinions on cancer treatment through panel discussions.
As a medical association formed in response to the COVID-19 pandemic, IVRA has become more solid in its content and format with each successive meeting.
Through this Malaysian academic conference, IVRA members and medical staff from each country were able to evaluate the event as a meaningful one that displays future directions for cancer treatment.
Han Sung-ho, CEO of AdipoLABs, which has developed and distributed ‘REMISSION 1℃’, a high-frequency cancer treatment device, said, “The proven effectiveness of ‘REMISSION 1℃’ shown at an international conference is confirmed by medical staff in each country to help relieve cancer from cancer.” “We were able to deliver a message of hope to the patients.” he said, adding, “This international academic conference served as an opportunity to raise the status of Korea’s medical technology.”
Meanwhile, this international conference was sponsored by the Korean Society of Thermal Medicine, Wonju Severance Christian Hospital, Korean Emergency Medicine Association, and Korean Balance Medicine Association.
출처: http://www.whosaeng.com/148559
